Literature DB >> 7772057

Chimeric constructs show that the unique N-terminal domain of the cyclic AMP phosphodiesterase RD1 (RNPDE4A1A; rPDE-IVA1) can confer membrane association upon the normally cytosolic protein chloramphenicol acetyltransferase.

G Scotland1, M D Houslay.   

Abstract

A novel plasmid was generated which allowed the expression of the cytosolic bacterial enzyme chloramphenicol acetyl transferase (CAT) in COS-7 cells. Upon transfection, the majority of the novel CAT activity was found in the cytosol fraction of COS cells. Chimeric molecules were made between N-terminal portions of the type IVA cyclic AMP-specific rat 'dunce-like' phosphodiesterase (RD1) (RNPDE4A1A; rPDE-IVA1) fused to CAT at its N-terminus. Expression in COS-7 cells of chimeras formed from 1-100RD1-CAT and 1-25RD1-CAT now showed CAT activity associated with the membrane fraction. In contrast, a chimera formed from 26-100RD1-CAT showed an identical expression pattern to native CAT, with the major fraction of CAT activity occurring in the cytosol fraction. Membrane-bound CAT activity provided by 1-100RD1-CAT and 1-25RD1-CAT was not released by either high-salt or washing treatments but was solubilized in a dose-dependent fashion by the non-ionic detergent Triton X-100. Subcellular fractionation of COS-7 cells showed that, as with RD1, the membrane-bound activity of the RD1-CAT chimera followed that of the plasma membrane marker 5'-nucleotidase. Plasmids containing chimeric cDNAs were exposed to a coupled transcription-translation system that, in addition to the full-length chimeras, was found to generate a range of N-terminal truncated species due to initiation at different methionine residues. Incubation of the mature protein products formed in this system with a COS cell membrane fraction showed that only those chimeric CAT constructs containing the first 25 amino acids of RD1 became membrane-associated. The unique 25 amino acid N-terminal domain of RD1 contains structural information that can confer membrane association upon an essentially soluble protein.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7772057      PMCID: PMC1136979          DOI: 10.1042/bj3080673

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  38 in total

1.  Attachment of a 40-base-pair G + C-rich sequence (GC-clamp) to genomic DNA fragments by the polymerase chain reaction results in improved detection of single-base changes.

Authors:  V C Sheffield; D R Cox; L S Lerman; R M Myers
Journal:  Proc Natl Acad Sci U S A       Date:  1989-01       Impact factor: 11.205

Review 2.  The G protein connection: molecular basis of membrane association.

Authors:  A M Spiegel; P S Backlund; J E Butrynski; T L Jones; W F Simonds
Journal:  Trends Biochem Sci       Date:  1991-09       Impact factor: 13.807

3.  Activation and phosphorylation of the 'dense-vesicle' high-affinity cyclic AMP phosphodiesterase by cyclic AMP-dependent protein kinase.

Authors:  E Kilgour; N G Anderson; M D Houslay
Journal:  Biochem J       Date:  1989-05-15       Impact factor: 3.857

4.  Indirect immunofluorescence localization of beta-adrenergic receptors and G-proteins in human A431 cells.

Authors:  H Y Wang; M Berrios; C C Malbon
Journal:  Biochem J       Date:  1989-10-15       Impact factor: 3.857

5.  CAT constructions with multiple unique restriction sites for the functional analysis of eukaryotic promoters and regulatory elements.

Authors:  B Luckow; G Schütz
Journal:  Nucleic Acids Res       Date:  1987-07-10       Impact factor: 16.971

6.  A simple phase-extraction assay for chloramphenicol acyltransferase activity.

Authors:  B Seed; J Y Sheen
Journal:  Gene       Date:  1988-07-30       Impact factor: 3.688

Review 7.  Empirical predictions of protein conformation.

Authors:  P Y Chou; G D Fasman
Journal:  Annu Rev Biochem       Date:  1978       Impact factor: 23.643

8.  Cloning and characterization of mammalian homologs of the Drosophila dunce+ gene.

Authors:  R L Davis; H Takayasu; M Eberwine; J Myres
Journal:  Proc Natl Acad Sci U S A       Date:  1989-05       Impact factor: 11.205

9.  Molecular cloning and expression of human myocardial cGMP-inhibited cAMP phosphodiesterase.

Authors:  E Meacci; M Taira; M Moos; C J Smith; M A Movsesian; E Degerman; P Belfrage; V Manganiello
Journal:  Proc Natl Acad Sci U S A       Date:  1992-05-01       Impact factor: 11.205

10.  A conserved tripeptide sorts proteins to peroxisomes.

Authors:  S J Gould; G A Keller; N Hosken; J Wilkinson; S Subramani
Journal:  J Cell Biol       Date:  1989-05       Impact factor: 10.539

View more
  12 in total

Review 1.  Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signalling network: benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developments.

Authors:  Thérèse Keravis; Claire Lugnier
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

2.  Targeted inhibition of cyclic AMP phosphodiesterase-4 promotes brain tumor regression.

Authors:  Patricia Goldhoff; Nicole M Warrington; David D Limbrick; Andrew Hope; B Mark Woerner; Erin Jackson; Arie Perry; David Piwnica-Worms; Joshua B Rubin
Journal:  Clin Cancer Res       Date:  2008-12-01       Impact factor: 12.531

3.  The SH3 domain of Src tyrosyl protein kinase interacts with the N-terminal splice region of the PDE4A cAMP-specific phosphodiesterase RPDE-6 (RNPDE4A5).

Authors:  J C O'Connell; J F McCallum; I McPhee; J Wakefield; E S Houslay; W Wishart; G Bolger; M Frame; M D Houslay
Journal:  Biochem J       Date:  1996-08-15       Impact factor: 3.857

Review 4.  Phosphodiesterase 4 inhibitors and the treatment of asthma: where are we now and where do we go from here?

Authors:  M A Giembycz
Journal:  Drugs       Date:  2000-02       Impact factor: 9.546

5.  Molecular cloning and transient expression in COS7 cells of a novel human PDE4B cAMP-specific phosphodiesterase, HSPDE4B3.

Authors:  E Huston; S Lumb; A Russell; C Catterall; A H Ross; M R Steele; G B Bolger; M J Perry; R J Owens; M D Houslay
Journal:  Biochem J       Date:  1997-12-01       Impact factor: 3.857

6.  Characterization of five different proteins produced by alternatively spliced mRNAs from the human cAMP-specific phosphodiesterase PDE4D gene.

Authors:  G B Bolger; S Erdogan; R E Jones; K Loughney; G Scotland; R Hoffmann; I Wilkinson; C Farrell; M D Houslay
Journal:  Biochem J       Date:  1997-12-01       Impact factor: 3.857

7.  Identification, characterization and regional distribution in brain of RPDE-6 (RNPDE4A5), a novel splice variant of the PDE4A cyclic AMP phosphodiesterase family.

Authors:  I McPhee; L Pooley; M Lobban; G Bolger; M D Houslay
Journal:  Biochem J       Date:  1995-09-15       Impact factor: 3.857

8.  Intracellular localization of the PDE4A cAMP-specific phosphodiesterase splice variant RD1 (RNPDE4A1A) in stably transfected human thyroid carcinoma FTC cell lines.

Authors:  L Pooley; Y Shakur; G Rena; M D Houslay
Journal:  Biochem J       Date:  1997-01-01       Impact factor: 3.857

9.  Suppression of human inflammatory cell function by subtype-selective PDE4 inhibitors correlates with inhibition of PDE4A and PDE4B.

Authors:  C D Manning; M Burman; S B Christensen; L B Cieslinski; D M Essayan; M Grous; T J Torphy; M S Barnette
Journal:  Br J Pharmacol       Date:  1999-12       Impact factor: 8.739

Review 10.  PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization.

Authors:  Miles D Houslay; David R Adams
Journal:  Biochem J       Date:  2003-02-15       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.